Antibody Targeted Therapies

This online course is designed to provide insights into the emerging technologies of antibody therapeutics, from design through to clinical success.

Widget Placeholderhttps://www.youtube.com/watch?v=ptnjKYEEheo

• Gain a comprehensive understanding of the antibody field and awareness of the historical aspects, current research and future direction of the development of antibodies as therapeutics.
• Provide an overview of the antibody fields ranging from structure and function, through to the recent development of antibodies as therapeutics including manufacture and clinical development.
• Gain insights to some of the issues that are required to develop antibodies from the bench to the clinic/market and raises issues with regard to manufacture, intellectual property and regulatory aspects.
• Effectively engage in cross-disciplinary collaborations with other professionals on how to formulate a strategy to design, develop and apply industry regulations and best practice to ensure quality and success

This MBI is recommended for:

• All professionals from industry and academic sectors (all disciplines including Chemists, (Cell) Biologists, Biochemists, Pharmacologists, Pharmacists, Medics, etc)
• Investors (Business and Pharma)
• Patent attorneys

Flexible Learning

Self-paced learning through a series of interactive audio presentations and animated videos. Delegates can access materials for up to 9 months allowing for flexible study.

Programme

1. ANTIBODY THERAPEUTICS: AN OVERVIEW
Overview of the antibody therapeutics field from discovery to clinical use, including a synopsis of the discovery and development of antibodies (biologics) as therapeutics and regulatory considerations.

2. ANTIBODY STRUCTURE & FUNCTION
Principles of the structure and function of antibodies.

3. ANTIBODY APPLICATIONS
Applications of antibodies as therapeutic entities.

4. ANTIBODY DIVERSITY
Insights into antibody diversity and its relevance in the development and production processes.

5. ANTIBODY FRAGMENTS
Focus on structural features of antibody fragments and their recent development as therapeutics.

6. ANTIBODY DRUG CONJUGATES (ADCS)
Overview of structural features of ADCs and their recent design and development as novel therapeutics for the oncology market. This topic also focuses on the optimization of the parameters required for the development of clinically useful ADCs.

7. ANTIBODY BIOPROCESSING
Principles of equipment selection and the latest methods for bioprocess manufacture of antibodies in the development process.

8. INTELLECTUAL PROPERTY: AN OVERVIEW
Insights into the mechanism and process of intellectual property protection (including antibodies) and provides real-life examples of the process by which protection can be challenged and lost or won.

Module Leader

Paul Dalby is a Professor of Biochemical Engineering and Biotechnology in the Department of Biochemical Engineering, University College London, UK.   Recent advances in molecular biology and computational modelling have opened the way to rapidly engineer therapeutic proteins and biocatalytic enzymes.  Paul has a background in protein chemistry and engineering and is currently using protein design and engineering strategies, such as directed evolution and bioinformatics, to improve biocatalytic enzymes and protein manufacturability.  He has developed novel high-throughput screening approaches for rapidly assessing protein stability, enzyme activity, formulation and freeze-drying.  He has also established new strategies for efficiently guiding the design of focused libraries of protein variants for directed evolution.  His work is closely linked to the IMRC and to BiCE, both of which are major research programmes in the Department for novel biopharmaceutical and biocatalytic processes respectively.  He has a first degree in Natural Sciences and a PhD in Protein Engineering, both from Cambridge University, plus postdoctoral experience in protein design and evolution from the University of Pennsylvania.